Monica Holmberg, PharmD, BCPS

The FDA has approved daridorexant (Quviviq; Idorsia Pharmaceuticals, US Inc) to treat adults with insomnia.

The FDA has approved abrocitinib tablets to treat adults with moderate-to-severe, refractory atopic dermatitis.

TherapeuticsMD, Inc has submitted a supplemental New Drug Application for estradiol and progesterone capsules 0.5 mg/100 mg (Bijuva) to the FDA.

The FDA has approved pilocarpine hydrochloride ophthalmic solution 1.25% (Vuity, Allergan, an AbbVie company) to treat presbyopia in adults.1

The FDA has approved Difelikefalin injection (Korsuva; Cara Therapeutics and Vifor Pharma) for the treatment of moderate-to-severe chronic kidney disease–associated pruritus in adults undergoing hemodialysis.

The FDA has approved atogepant oral tablets (Qulipta; AbbVie) for the preventive treatment of episodic migraines in adults.

The FDA has approved zanubrutinib (Brukinsa, BeiGene) for the treatment of adults with Waldenström macroglobulinemia (WM).

The FDA approves anifrolumab-fnia injection (Saphnelo; AstraZeneca) for the treatment of adults with moderate to severe system- ic lupus erythematosus (SLE) who are receiving standard therapy.

The FDA has approved Qelbree (viloxazine extended-release capsules; Supernus Pharmaceuticals, Inc) for the treatment of attention-deficit/hyperactivity disorder (ADHD) in pediatric patients aged 6 to 17 years.

Evkeeza has been approved as an adjunct to other low-density lipoprotein cholesterol-lowering therapies to treat patients 12 years and older with homozygous familial hypercholesterolemia.

The FDA has approved Verquvo (vericiguat; Merck) tablets for adults with chronic heart failure.

The FDA has approved Gemtesa (vibegron; Urovant Sciences) tablets to treat overactive bladder (OAB) with symptoms of urge urinary incontinence (UUI), urgency, and urinary frequency.

RET fusions and mutations drive many types of cancer.

The FDA has approved Eysuvis (loteprednol etabonate ophthalmic suspension) 0.25% for the short-term treatment of the signs and symptoms of dry eye disease.

Inqovi (decitabine and cedazuridine) tablets from Astex Pharmaceuticals, Otsuka Pharmaceutical, and Taiho Oncology are indicated to treat adults with myelodysplastic syndromes.

The FDA has approved Rukobia (fostemsavir) for the treatement of human immunodeficiency virus 1 (HIV-1) infection.

As PD progresses, patients using levodopa/carbidopa may experience off-time episodes between medication doses, when the medication is not working and motor symptoms, such as difficulty walking, slowed movement, and tremor, return.

The FDA has approved Barhemsys (amisulpride) injection from Acacia Pharma for the prevention and treatment of postoperative nausea and vomiting (PONV) in adults.

The FDA has approved Nurtec ODT (rimegepant) from Biohaven Pharmaceuticals to treat acute migraines with or without aura in adults.

The FDA has approved Nexletol (bempedoic acid), a nonstatin cholesterol-lowering agent, in adults who require additional lowering of low-density lipoprotein cholesterol (LDL-C).

Caplyta is an atypical antipsychotic and is thought to exert its effect through a combination of antagonist activity at central serotonin 5-HT2A receptors and postsynaptic antagonist activity at central dopamine D2 receptors.

Palforzia is an oral immunotherapy agent for the mitigation of allergic reactions, including anaphylaxis, that may occur with accidental exposure to peanuts.

The fda has approved talicia (amoxicillin, omeprazole magnesium, and rifabutin) for the treatment of Helicobacter pylori infection in adults.

The FDA has approved Rinvoq (upadacitinib) to treat moderate to severe rheumatoid arthritis (RA) in adults who have had an inadequate response or intolerance to methotrexate (MTX).

The FDA has approved Xenleta (Lefamulin, from Nabriva Therapeutics) for the treatment of adults with community-acquired bacterial pneumonia (CABP) caused by susceptible microorganisms.

The FDA has approved Sunosi (solriamfetol) from Jazz Pharmaceuticals, Inc, to improve wakefulness in adults with excessive daytime sleepiness associated with narcolepsy or obstructive sleep apnea (OSA).

The FDA has approved Descovy (emtricitabine 200-mg and tenofovir alafenamide 25-mg tablets) for HIV-1 pre-exposure prophylaxis (PrEP).